All In Biotech

Drug Trial Radar · NCT04630522

Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

A Randomized, Open-Label, Dose-finding, Multi-centre, Phase Ib Study toEvaluate the Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 295 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

295

Actual

Start

Oct 31, 2020

Primary completion

Mar 31, 2023

Study completion Mar 31, 2023

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Nov 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, dose-finding, multi-centre, phase Ⅰb study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors.

Conditions

  • Bone Metastases From Solid Tumors

Interventions

  • Drug: JMT103- 120 mg SC Q4WDrug

    JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.

  • Drug: JMT103- 120 mg SC Q8WDrug

    JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.

  • Drug: JMT103- 180 mg SC Q8WDrug

    JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.

  • Dietary Supplement: Calcium Dietary Supplement: Vitamin DDietary supplement

    Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change of urinary N-terminal telopeptide of type 1 collagen/creatine (U-NTX/Cr) from baseline to week 13Time frame: From enrollment to week 13.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.